Document text
Principal Investigator: Henry M. Colecraft
Organization: COLUMBIA UNIVERSITY HEALTH SCIENCES
Fiscal Year: 2020
Award: $337,499
Funding agency: National Heart Lung and Blood Institute
Summary
This proposal is for a COVID-19-related Administrative Supplement for RO1HL142111, “Ubiquitin regulation of
K Channels in Health and Disease”. We propose to adapt/apply tools and approaches including, nanobody
development and optical assays of membrane proteins, that we have developed for studies in the parent proposal
to develop novel solutions for COVID-19. There is an ongoing global pandemic in which a novel Coronavirus,
SARS-CoV-2, causes Coronavirus Disease-2019 (COVID-19) that is lethal to a subset of the infected population.
To date, there are >1.5 million confirmed COVID-19 cases worldwide with >70,000 fatalities. In the United States,
best case scenario projections indicate 100,000 – 240,000 lives will be lost to COVID-19, with a worst case
scenario of >2 million deaths. The current pandemic follows two other regional outbreaks of coronaviruses
responsible for severe acute respiratory syndrome (SARS-CoV) in 2002, and Middle Eastern respiratory
syndrome (MERS-CoV) in 2012, that caused epidemics with fatality rates of 10% and 36%, respectively. All three
coronaviruses represent examples of animal to human transmission of infection. Given a high zoonotic reservoir
of novel coronaviruses and persistence of close animal/human contact in various parts of the world, the chances
of future viral epidemics/pandemics beyond the current crisis is high. Hence, fatal diseases caused by viral
infections represent current and future widespread public health challenges, highlighting an urgent need for
general strategies that can combat not only COVID-19 but also other future viral outbreaks. SARS-CoV-2 is an
enveloped virus that gains access to host cells by using a receptor binding domain (RBD) on a viral surface spike
protein (S) to bind to membrane-bound angiotensin-converting enzyme 2 (ACE2) receptors on target cells.
Preventing the SARS-CoV-2 S protein/ACE2 receptor interaction is the main principle behind the beneficial
effects of neutralizing antibodies in recovered patients, and the scientific premise for an ongoing clinical trial for
administration of soluble ACE2 ectodomain. There are ongoing efforts to develop neutralizing monoclonal
antibodies (mAb) against SARS-CoV-2 S protein that disrupt interaction with ACE2. While potentially effective,
limitations of this approach include high cost, time-consuming, incompatibility with inhalation formulations, and
potential for viral mutations that result in escape from mAb-mediated neutralization. This proposal is based on
the hypothesis that engineered single-domain antibodies (nanobodies) with high avidity for SARS-CoV-2 S
protein can be generated to overcome some of the limitations of neutralizing mAbs and provide potential
therapeutic leads for COVID-19. We propose three aims: 1) Isolate and characterize neutralizing and non-
neutralizing nanobodies against SARS-CoV-2 S protein; 2) Develop cell-based high throughput fluorescence
assay to probe SARS-CoV-2 S protein/ACE2 interaction and internalization; 3) Comparatively evaluate the
capacity of engineered nanobodies to disrupt SARS-CoV-2 S protein/ACE2 interaction and internalization
Terms: <2019 novel coronavirus><2019-nCoV><APF-1><ATP-Dependent Proteolysis Factor 1><Administrative Supplement><Affinity><Angiotensin Converting Enzyme><Angiotensin I-Converting Enzyme><Animals><Assay><Avidity><Bats><Binding><Bioassay><Biologic Assays><Biological Assay><CD143 Antigens><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID19><COVID19 epidemic><COVID19 pandemic><Camels><Carboxycathepsin><Cell Body><Cells><Cellular Assay><Cessation of life><Chimera Protein><Chimeric Proteins><Chiroptera><Clinical Treatment Moab><Clinical Trials><CoV emergence><Consumption><Coronaviridae><Coronavirus><Data><Death><Development><Dipeptidyl Peptidase A><Disease><Disease Outbreaks><Disorder><Endocytosis><Engineering><Epidemic><Fatality rate><Fluorescence><Formulation><Fusion Protein><Future><Genetic Alteration><Genetic Change><Genetic defect><HMG-20><Health><High Mobility Protein 20><Human><Infection><Inhalation><Inhaling><K channel><Kininase A><Kininase II><Lead><Libraries><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Mediating><Membrane><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modern Man><Molecular Interaction><Monitor><Monoclonal Antibodies><Mutation><Optics><Outbreaks><Parents><Pathogenesis><Patients><Pb element><Peptidyl-Dipeptidase A><Population><Potassium Channel><Potassium Ion Channels><Process><Production><Property><Protein Biochemistry><Protein Trafficking><Protein/Amino Acid Biochemistry><Proteins><Public Health><Receptor Protein><Regulation><Reporting><Research Resources><Resources><SARS><SARS Virus><SARS corona virus><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV disease><SARS-CoV-2><SARS-CoV2><SARS-Related Coronavirus><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe acute respiratory syndrome coronavirus 2><Surface><Surface Proteins><Syndrome><Therapeutic><Time><Transmission><Ubiquitin><United States><Viral><Viral Diseases><Virus Diseases><Wuhan coronavirus><Yeasts><Zoonoses><Zoonotic><Zoonotic Infection><base><cell assay><combat><comparative><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><coronavirus emergence><cost><developmental><efficacy testing><emergent CoV><emergent coronavirus><emerging CoV><emerging coronavirus><genome mutation><heavy metal Pb><heavy metal lead><inhibitor><inhibitor/antagonist><mAbs><membrane structure><nCoV><nanobodies><nanobody><neutralizing antibody><neutralizing mAb><neutralizing monoclonal antibodies><new CoV><new coronavirus><novel><novel CoV><novel coronavirus><optical><pandemic><pandemic disease><prevent><preventing><protein transport><receptor><receptor binding><receptor bound><respiratory><sdAb><severe acute respiratory syndrome-CoV><single domain antibodies><tool><transmission process><viral infection><virus envelope><virus infection><virus-induced disease>